Call Us Today: 1(844) 391-5164

For over two decades, our firm has successfully represented consumers, stockholders and investors to secure millions of dollars in recoveries and corporate governance reforms.

Move your mouse pointer over the company names listed below for a short description of our current case investigations. We welcome you to contact us for more information regarding our current case investigations.

SEND MESSAGE

Current Case Investigations:

This is an investigation related to allegations of sexual misconduct by the company chairman and CEO.

This investigation is related to a July 27, 2018, media outlets report that The New Yorker would shortly publish an article detailing allegations of sexual misconduct by CBS chairman and chief executive officer Leslie Moonves. That same day, CBS announced that it would investigate the allegations against Moonves, stating that "[a]ll [allegations] of personal misconduct are to be taken seriously." On this news, CBS's stock price fell $3.52, or 6.12%, to close at $54.01 on July 27, 2018.

For more information call us at 1(844) 391-5164 toll free. You can also send us a message in the form above or email us at info@yatesclassaction.com. Please indicate to us your inquiry is about CBS.

This is an investigation related to the company’s disclosure that it was unable to make required payments to its merchant and fulfillment processors as part of the company’s MoviePass service.

A complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: the company was touting MoviePass’ valuation and path to profitability; MoviePass’ business model was not sustainable; consequently, the company would run out of cash; and defendants’ actions were only reducing shareholder value. Based on this news, the company’s share price fell by more than 70% the same day. The Class Period is August 15, 2017 through July 26, 2018. The deadline for appointment of a lead plaintiff is October 1, 2018.

For more information call us at 1(844) 391-5164 toll free. You can also send us a message in the form above or email us at info@yatesclassaction.com. Please indicate to us your inquiry is about Helios.

This is an investigation related to the company’s financial misstatement and material weakness in its internal controls over financial reporting.

A complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: Rockwell was aware that the Centers for Medicare and Medicaid Services would not pursue Rockwell’s proposal for separate reimbursement for Triferic; the estimated reserves in Rockwell’s Form 10-Q for the quarter ended March 31, 2018 were misstated; there was a material weakness in Rockwell’s internal controls over financial reporting; consequently, Rockwell’s internal controls over financial reporting were ineffective during the Class Period; and defendant Robert L. Chioini, Rockwell’s former Chief Executive Officer, withheld material information regarding Triferic from Rockwell’s auditor, corporate counsel and five independent directors of Rockwell’s Board. The Class Period is March 16, 2018 through June 26, 2018. The deadline for appointment of a lead plaintiff is September 25, 2018.

For more information call us at 1(844) 391-5164 toll free. You can also send us a message in the form above or email us at info@yatesclassaction.com. Please indicate to us your inquiry is about Rockwell.

This is an investigation related to the company’s IGNITE3 Phase 3 clinical trial of eravacycline in complicated urinary tract infection ("cUTI").

A complaint alleges that Tetraphase was increasing the patient enrollment in its IGNITE3 trial from 1,000 patients to 1,200 patients to meet the trial's primary endpoints (within the 10% non-inferiority margin); the enrollment of more patients in the trial indicated that the existing population was inadequate to meet the trial's primary endpoints; and consequently, defendants' statements about Tetraphase's business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis. On this news, Tetraphase's stock price fell $3.28 per share, or 60.41%, to close at $2.15 per share on February 14, 2018. Then, on March 6, 2017, the company advised investors that given the results of the IGNITE3 study, the Company did not plan to further evaluate and develop an oral formulation of eravacycline for the treatment of cUTI. The Class Period is March 8, 2017 through February 13, 2018 and/or traceable to the company's July 2017 secondary public offering. The deadline for appointment of a lead plaintiff is September 25, 2018.

For more information call us at 1(844) 391-5164 toll free. You can also send us a message in the form above or email us at info@yatesclassaction.com. Please indicate to us your inquiry is about Tetraphase.

This is an investigation related to alleged misleading stock promotion tactics to boost the company’s stock price.

A complaint alleges that Vuzix used unlawful stock promotion tactics to boost the company's stock price and Vuzix used misleading stock promotion tactics to raise nearly $30 million at an all-time high share price. On this news, the Company's share price fell $1.70 per share, or more than 22%, on heavy trading volume, over the course of three trading sessions, to close on March 21, 2018 at $5.95 per share. The Class Period is November 9, 2017 through March 20, 2018 and/or traceable to the company’s January 2018 secondary public offering. The deadline for appointment of a lead plaintiff is September 24, 2018.

For more information call us at 1(844) 391-5164 toll free. You can also send us a message in the form above or email us at info@yatesclassaction.com. Please indicate to us your inquiry is about Vuzix.

This is an investigation related to failure to disclose the company was being investigated by the SEC.

A complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that the company was either already or was likely to soon become the subject of a Securities and Exchange Commission investigation. On July 11, 2018, Zion disclosed that the Company had received a subpoena to produce documents from the Fort Worth office of the U.S. Securities and Exchange Commission, informing Zion of the existence of a non-public, fact-finding inquiry into the Company. On this news, Zion's stock price fell $0.44, or 11%, to close at $3.56 on July 12, 2018. The Class Period is March 12, 2018 through July 10, 2018. The deadline for appointment of a lead plaintiff is October 8, 2018.

For more information call us at 1(844) 391-5164 toll free. You can also send us a message in the form above or email us at info@yatesclassaction.com. Please indicate to us your inquiry is about Zion.

Call us anytime toll free at 1(844) 391-5164.